About
Eveliqure Biotechnologies is an Austrian biotech company developing live attenuated, orally delivered vaccines to prevent diarrhoeal diseases, with its lead candidate ShigETEC targeting Shigella and enterotoxigenic E. coli (ETEC) currently in Phase 2b clinical trials.
Explore Eveliqure Biotechnologies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.